Sipuleucel-T (APC8015, trade name Provenge),   manufactured by Dendreon Corporation, is a cell-based cancer immunotherapy for prostate cancer (CaP).
PROVENGE—an advanced prostate cancer treatment that works differently from hormone therapy or chemotherapy. Read more at Provenge.com
Information from the FDA about the approval of this drug and the clinical trials that led to the approval.
Sipuleucel-T, an autologous active cellular immunotherapy, has shown evidence of efficacy in reducing the risk of death among men with metastatic castration-resistant ...
PROVENGE PROVENGE ® (sipuleucel-T) Is FDA Approved. PROVENGE is the first and only FDA approved immunotherapy IMMUNOTHERAPY Treatment that helps the immune system ...
April 29, 2010 Approval Letter - Provenge Indication: For the treatment of asymptomatic or minimally symptomatic metastatic castrate resistant (hormone refractory ...
Easy to read patient leaflet for sipuleucel-t. Includes indications, proper use, special instructions, precautions, and possible side effects.
FDA Approval for Sipuleucel-T. Use in Cancer. Sipuleucel-T is approved to treat: Prostate cancer that has metastasized (spread to other parts of the body).
Sipuleucel-T side effects are often predictable in terms of their onset, duration, and severity.
BlueCross BlueShield of Tennessee Medical Policy Manual Sipuleucel-T. DESCRIPTION. Sipuleucel-T is the first autologous cellular immunotherapy approved for use in the ...